检索结果-南通市图书馆

Hepatocellular carcinoma in HCV - liver cirrhosis before and after successful DAA treatment

Hepatoma Research 2019年第10期5卷 1-5页

作者： Zahari Krastev deian jelev Donika Krasteva Jordan Genov Teodora Komitova Clinic of Gastroenterology University Hospital Sv.Ivan RilskiMedical UniversitySofia 1431Bulgaria Clinic of Gastroenterology University Hospital Tsaritsa Yoanna-ISULMedical UniversitySofia 1527Bulgaria

Chronic hepatitis C virus(HCV)infection is a major cause of liver cirrhosis and hepatocellular carcinoma(HCC)*** recent advancement of direct-acting Antiviral Agents(DAAs)in hepatitis C therapy,resulted in sustained virological response rates of over 90%in treated patients in different stages of liver *** efficacy of DAAs treatment has also been confirmed in real-life cohorts that include subjects with decompensated cirrhosis and therefore seems a promising step to a significant reduction in the recurrence of HCC in patients who achieved complete destruction of the HCC nodules by local *** present a 72-year old patient with HCV-related liver cirrhosis who successfully responded to DAAs treatment after complete destruction of an early HCC nodule.

关键词： Hepatocellular carcinoma hepatitis C virus infection Direct-acting Antiviral Agents hepatocellular carcinoma recurrence

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Ombitasvir, paritaprevir, ritonavir, dasabuvir and ribavirin in cirrhosis after complete destruction of hepatocellular carcinoma

引用

World Journal of Gastroenterology 2016年第8期22卷 2630-2635页

作者： Zahariy Krastev deian jelev Krasimir Antonov Tanya Petkova Evelina Atanasova Nadezhda Zheleva Bojidar Tomov Yana Boyanova Lyudmila Mateva Clinic of Gastroenterology University Hospital "St. Ivan Rilski"

We observed a sustained viral response(SVR) of ombitasvir/paritaprevir/ritonavir, dasabuvir and ribavirin therapy, for 12 wk, in two cases with compensated liver cirrhosis and fully destroyed early hepatocellular carcinoma(HCC). Patients were infected with hepatitis C virus(HCV) genotype 1b and were previous null responders/relapsers to interferon-alpha/ribavirin(IFN/RBV). There was a rapid suppression of HCV RNA to undetectable levels within the first two treatment weeks. SVR was achieved even after marked reduction of the RBV dose. The treatment was well tolerated. Both subjects experienced worsening of liver disease during therapy, in different patterns: severe, transient, predominantly direct hyperbilirubinemia without cytolysis(case 1) or progressive increase of aminotransferases(grade 4) without severe hyperbilirubinemia(case 2).Adverse events spontaneously resolved. The patients remained in a good clinical condition without hepatic decompensation. There was no re-occurrence of HCC. This is the first report for treatment of HCV cirrhosis after complete HCC destruction.

关键词： Ombitasvir Paritaprevir Ritonavir Dasabuvir Ribavirin Hepatitis C virus cirrhosis Hepatocellular carcinoma

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：